Thinking of joining a study?

Register your interest

Become a volunteer?

NCT06887348 | NOT YET RECRUITING | Melanoma

A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3
Sponsor:

Replimune Inc.

Brief Summary:

This is a noninterventional, observational, long-term follow-up (LTFU) study. Patients in this study will be followed for 5 years from enrollment on this study to assess potential delayed risks of RPx products. Eligible participants for this LTFU study include patients who received at least 1 dose of an RPx product under the interventional parent study. Patients will be rolled over into this LTFU study after completion of the Replimune-sponsored parent study (ie, either completion of the LTFU in the parent study or withdrawal from the parent study). All patients in ongoing RPx studies will be asked to participate in this LTFU study so that the Sponsor can evaluate potential delayed risks.

Condition or disease

Melanoma

Metastatic Melanoma

Advanced Solid Tumor

Hepatocellular Carcinoma

Intervention/treatment

Observational study with no interventions

Detailed Description:

Long-term outcomes include detection of delayed adverse event(s) for any new malignancy(ies), new incidence or exacerbation of a pre-existing neurologic disorder, rheumatologic or other autoimmune disorder, hematologic disorder, new incidence of infection related to RPx product and new incidence of herpetic-like infection. Patients with a suspected herpetic infection will be asked to provide a sample of the area of the suspected infection (using a swab), and also may be asked to provide additional biological samples (eg, a blood or urine sample to determine presence of RPx.) No study interventions will be administered in this observational study. Patients will be contacted by telephone every 3 months (Q3M) for 5 years from enrollment on this study. Participant visits may occur in person, over the phone, by video conference, or other technology.

Study Type : OBSERVATIONAL
Estimated Enrollment : 50 participants
Official Title : Long-term Safety Outcomes in Patients Treated With Replimune Oncolytic Immunotherapy Products
Actual Study Start Date : 2025-06
Estimated Primary Completion Date : 2030-12
Estimated Study Completion Date : 2035-12

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • Patients are eligible for inclusion in the study only if they meet all of the following criteria
    • 1. Patient has received at least 1 dose of an RPx product and has completed or discontinued participation in the parent study.
    • 2. Patient or patient's legal guardian has provided signed informed consent (or assent) as , which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
    Exclusion Criteria
    • Patients are excluded from the study if the following criterion applies
      • 1. Cannot comply with the requirements of the study.
A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3

Location Details

NCT06887348

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

No Location Found